S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The single greatest medical breakthrough of all time? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The single greatest medical breakthrough of all time? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The single greatest medical breakthrough of all time? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The single greatest medical breakthrough of all time? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The single greatest medical breakthrough of all time? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The single greatest medical breakthrough of all time? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
The single greatest medical breakthrough of all time? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The single greatest medical breakthrough of all time? (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
NASDAQ:RGEN

Repligen - RGEN Stock Forecast, Price & News

$186.05
-2.12 (-1.13%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$180.11
$189.58
50-Day Range
$167.03
$220.56
52-Week Range
$137.21
$274.09
Volume
389,505 shs
Average Volume
678,614 shs
Market Capitalization
$10.33 billion
P/E Ratio
64.16
Dividend Yield
N/A
Price Target
$249.80

Repligen MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
34.3% Upside
$249.80 Price Target
Short Interest
Bearish
6.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.19
Upright™ Environmental Score
News Sentiment
0.16mentions of Repligen in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$11.11 M Sold Last Quarter
Proj. Earnings Growth
-4.09%
From $3.18 to $3.05 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

280th out of 1,034 stocks

Biological Products, Except Diagnostic Industry

43rd out of 171 stocks

RGEN stock logo

About Repligen (NASDAQ:RGEN) Stock

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

RGEN Stock News Headlines

Analysts Set Repligen Co. (NASDAQ:RGEN) Price Target at $249.80
BIIB or RGEN: Which Is the Better Value Stock Right Now?
BIIB vs. RGEN: Which Stock Is the Better Value Option?
Repligen (RGEN) Q3 Earnings and Revenues Top Estimates
Repligen to Report Third Quarter 2022 Financial Results
See More Headlines
Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

RGEN Company Calendar

Last Earnings
10/28/2021
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/16/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RGEN
CUSIP
75991610
Employees
1,852
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$249.80
High Stock Price Forecast
$275.00
Low Stock Price Forecast
$213.00
Forecasted Upside/Downside
+34.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$128.29 million
Pretax Margin
25.08%

Debt

Sales & Book Value

Annual Sales
$670.53 million
Cash Flow
$4.03 per share
Book Value
$33.05 per share

Miscellaneous

Free Float
54,913,000
Market Cap
$10.33 billion
Optionable
Optionable
Beta
1.04

Social Links


Key Executives

  • Mr. Anthony J. HuntMr. Anthony J. Hunt (Age 58)
    Pres, CEO & Director
    Comp: $2.1M
  • Mr. Jon K. SnodgresMr. Jon K. Snodgres (Age 56)
    Chief Financial Officer
    Comp: $860.08k
  • Mr. James R. BylundMr. James R. Bylund (Age 58)
    Chief Operating Officer
    Comp: $725.55k
  • Ms. Christine GebskiMs. Christine Gebski (Age 53)
    Sr. VP of Filtration & Chromatography
    Comp: $685.06k
  • Mr. Ralf KuriyelMr. Ralf Kuriyel (Age 63)
    Sr. VP of R&D
    Comp: $708.15k
  • Ms. Sondra S. Newman
    Global Head of Investor Relations
  • Ms. Kimberly Cornwell
    Global Head of Legal & Gen. Counsel
  • Mr. Stephen Tingley
    VP & Head of Global Sales
  • Ms. Rachel Goodrich
    VP of Marketing
  • Mr. James Slaughter
    Chief HR Officer













RGEN Stock - Frequently Asked Questions

Should I buy or sell Repligen stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RGEN shares.
View RGEN analyst ratings
or view top-rated stocks.

What is Repligen's stock price forecast for 2023?

5 analysts have issued 12-month target prices for Repligen's shares. Their RGEN share price forecasts range from $213.00 to $275.00. On average, they expect the company's share price to reach $249.80 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price.
View analysts price targets for RGEN
or view top-rated stocks among Wall Street analysts.

How have RGEN shares performed in 2022?

Repligen's stock was trading at $264.84 at the beginning of the year. Since then, RGEN stock has decreased by 29.8% and is now trading at $186.05.
View the best growth stocks for 2022 here
.

When is Repligen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our RGEN earnings forecast
.

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) released its quarterly earnings data on Thursday, October, 28th. The biotechnology company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.14. The biotechnology company earned $178.22 million during the quarter, compared to analysts' expectations of $163.97 million. Repligen had a net margin of 20.76% and a trailing twelve-month return on equity of 10.98%. The company's revenue for the quarter was up 89.5% on a year-over-year basis. During the same period last year, the company earned $0.40 EPS.

What guidance has Repligen issued on next quarter's earnings?

Repligen issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of $3.15-$3.20 for the period, compared to the consensus EPS estimate of $3.20. The company issued revenue guidance of $795.00 million-$805.00 million, compared to the consensus revenue estimate of $803.99 million.

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Who are Repligen's major shareholders?

Repligen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.24%), Price T Rowe Associates Inc. MD (6.59%), Sands Capital Management LLC (2.95%), WCM Investment Management LLC (2.74%), State Street Corp (2.51%) and Artisan Partners Limited Partnership (2.11%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, John Cox, Jon Snodgres, Karen A Dawes, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends
.

How do I buy shares of Repligen?

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $186.05.

How much money does Repligen make?

Repligen (NASDAQ:RGEN) has a market capitalization of $10.33 billion and generates $670.53 million in revenue each year. The biotechnology company earns $128.29 million in net income (profit) each year or $2.90 on an earnings per share basis.

How many employees does Repligen have?

The company employs 1,852 workers across the globe.

Does Repligen have any subsidiaries?
The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.
Read More
How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for the company is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115.

This page (NASDAQ:RGEN) was last updated on 12/4/2022 by MarketBeat.com Staff